SCHEMBL7043645

SCHEMBL7043645

CCOC(=O)C(=O)c1sccc1I

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
KMT2A Q03164 5/20 0.43
GAA P10253 3/20 0.43
KDM4E B2RXH2 3/20 0.42
PKM P14618 4/20 0.42
NPSR1 Q6W5P4 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
MAPT P10636 4/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
LMNA P02545 1/20 0.39
CYP2D6 P10635 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
MEN1 O00255 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
HPGD P15428 1/20 0.38
NFKB1 P19838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8501054 0.83 GSK3B (0.51) ALDH1A1KMT2AGAAKDM4EPKM
SCHEMBL27756118 0.81 ALDH1A1 (0.44) ALDH1A1KMT2AGAAKDM4EPKM
SCHEMBL7041650 0.80 PKM (0.46) ALDH1A1KMT2AGAAKDM4EPKM
SCHEMBL7043180 0.80 ALDH1A1 (0.46) ALDH1A1KMT2AGAAKDM4EPKM
SCHEMBL12172196 0.79 TSHR (0.49) ALDH1A1KMT2AGAAKDM4EPKM
SCHEMBL8010614 0.78 ALDH1A1 (0.41) ALDH1A1KMT2AGAAKDM4EPKM
SCHEMBL1582315 0.78 ALDH1A1 (0.41) ALDH1A1KMT2AGAAKDM4EPKM
SCHEMBL25078299 0.73 KMT2A (0.59) ALDH1A1KMT2AGAAKDM4EPKM
SCHEMBL7042196 0.72 PTPN2 (0.40) ALDH1A1KMT2AGAAKDM4ENPSR1
SCHEMBL4024304 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613786-B2 Treating urinary incontinence, asthma, irritable bowel syndrome or male erectile dysfunction BRISTOL-MYERS SQUIBB COMPANY 2003-09-02 US disclosed
US-20030144333-A1 Thiophenyl triazol-3-one derivatives as smooth muscle relaxants HEWAWASAM PIYASENA (US) 2003-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144333-A1 Thiophenyl triazol-3-one derivatives as smooth muscle relaxants PDE3A, ADRB2, ADRB3 ALDH1A1 1237/4885KMT2A 981/4885GAA 4519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.